Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: A meta-analysis

Expert Review of Anticancer Therapy

Volumn 11, Issue 8, 2011, Pages 1197-1207

  Cibula, David ^a   Zikan, Michal ^a   Dusek, Ladislav ^b   Majek, Ondrej ^b  

^a CHARLES UNIVERSITY   (Czech Republic)

^b MASARYK UNIVERSITY   (Czech Republic)

Author keywords

BRCA1; BRCA2; breast cancer; combined oral contraceptives; ovarian cancer

Indexed keywords

ANTINEOPLASTIC AGENT; ORAL CONTRACEPTIVE AGENT;

ARTICLE; BREAST CANCER; CANCER INVASION; CANCER PREVENTION; CANCER RISK; CANCER SUSCEPTIBILITY; CHEMOPROPHYLAXIS; COHORT ANALYSIS; DRUG EFFECT; FAMILIAL CANCER; GENE MUTATION; GENETIC ASSOCIATION; GENETIC RISK; HETEROZYGOTE; HIGH RISK POPULATION; HUMAN; METASTASIS POTENTIAL; OVARY CANCER; PARENT COUNSELING; POPULATION BASED CASE CONTROL STUDY; PREVALENCE; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK MANAGEMENT; RISK REDUCTION; SALPINGOOOPHORECTOMY; TREATMENT CONTRAINDICATION; TREATMENT DURATION; TUMOR SUPPRESSOR GENE;

BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CONTRACEPTIVES, ORAL; FEMALE; HETEROZYGOTE; HUMANS; MUTATION; OVARIAN NEOPLASMS; RISK FACTORS;

EID: 80052326782     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.11.38     Document Type: Article

References (44)

1. Beral V, Doll R, Hermon C et al. Ovarian cancer and oral contraceptives: Collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet 371, 303-314 (2008). Largest meta-analysis available demonstrating a significantly decreased ovarian cancer risk in combined oral contraceptive (COC) users.
2. Cibula D, Gompel A, Mueck AO et al. Hormonal contraception and risk of cancer. Hum. Reprod. Update 16(6), 631-650 (2010).
3. King MC, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302, 643-646 (2003).
4. Rebbeck TR, Lynch HT, Neuhausen SL et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N. Engl. J. Med. 346, 1616-1622 (2002).
5. Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J. Natl Cancer Inst. 101, 80-87 (2009). Largest meta-analysis available demonstrating significant risk reduction of ovarian or Fallopian tube cancer (hazard ratio [HR]: 0.21) and breast cancer (HR: 0.49) associated with salpingo-oophorectomy in BRCA1/2 mutation carriers.
6. Harris RJ, Bradburn MJ, Deeks JJ et al. Metan: Fixed- and random-effects meta-analysis. Stata. J. 8, 3-28 (2008).
7. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 327, 557-560 (2003).
8. StataCorp. Stata 10.1. 10.1 ed. College Station, TX, USA. StataCorp (2007).
9. McLaughlin JR, Risch HA, Lubinski J et al. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: A case-control study. Lancet Oncol. 8, 26-34 (2007). Largest study available showing a significant ovarian cancer risk reduction in COC users who are carriers of the BRCA1 (odds ratio [OR]: 0.56; p < 0001) or BRCA2 (OR: 0.39; p < 0.0004) mutation.
10. Gronwald J, Byrski T, Huzarski T et al. Influence of selected lifestyle factors on breast and ovarian cancer risk in BRCA1 mutation carriers from Poland. Breast Cancer Res. Treat. 95, 105-109 (2006).
11. Whittemore AS, Balise RR, Pharoah PD et al. Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations. Br. J. Cancer 91, 1911-1915 (2004).
12. Runnebaum IB, Wang-Gohrke S, Vesprini D et al. Progesterone receptor variant increases ovarian cancer risk in BRCA1 and BRCA2 mutation carriers who were never exposed to oral contraceptives. Pharmacogenetics 11, 635-638 (2001).
13. Narod SA, Risch H, Moslehi R et al. Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. N. Engl J. Med. 339, 424-428 (1998).
14. Antoniou AC, Rookus M, Andrieu N et al. Reproductive and hormonal factors, and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: Results from the International BRCA1/2 Carrier Cohort Study. Cancer Epidemiol. Biomarkers Prev. 18, 601-610 (2009).
15. McGuire V, Felberg A, Mills M et al. Relation of contraceptive and reproductive history to ovarian cancer risk in carriers and noncarriers of BRCA1 gene mutations. Am. J. Epidemiol. 160, 613-618 (2004).
16. Modugno F, Moslehi R, Ness RB et al. Reproductive factors and ovarian cancer risk in Jewish BRCA1 and BRCA2 mutation carriers (United States). Cancer Causes Control 14, 439-446 (2003).
17. Modan B, Hartge P, Hirsh-Yechezkel G et al. Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. N. Engl J. Med. 345, 235-240 (2001).
18. Biglia N, Mariani L, Ponzone R, Sismondi P. Oral contraceptives, salpingo-oophorectomy and hormone replacement therapy in BRCA1-2 mutation carriers. Maturitas 60, 71-77 (2008).
19. Figueiredo JC, Bernstein L, Capanu M et al. Oral contraceptives, postmenopausal hormones, and risk of asynchronous bilateral breast cancer: The WECARE Study Group. J. Clin. Oncol. 26, 1411-1418 (2008).
20. Bermejo-Perez MJ, Marquez-Calderon S, Llanos-Mendez A. Effectiveness of preventive interventions in BRCA1/2 gene mutation carriers: A systematic review. Int. J. Cancer 121, 225-231 (2007).
21. Nusbaum R, Isaacs C. Management updates for women with a BRCA1 or BRCA2 mutation. Mol. Diagn. Ther. 11, 133-144 (2007).
22. Friedman LC, Kramer RM. Reproductive issues for women with BRCA mutations. J. Natl Cancer Inst. Monogr. 16, 83-86 (2005).
23. Grenader T, Peretz T, Lifchitz M, Shavit L. BRCA1 and BRCA2 germ-line mutations and oral contraceptives: To use or not to use. Breast 14, 264-268 (2005).
24. Jernstrom H, Loman N, Johannsson OT et al. Impact of teenage oral contraceptive use in a population-based series of early-onset breast cancer cases who have undergone BRCA mutation testing. Eur. J. Cancer 41, 2312-2320 (2005).
25. Kaduri L, Gibs M, Hubert A et al. Genetic testing of breast and ovarian cancer patients: Clinical characteristics and hormonal risk modifiers. Eur. J. Obstet. Gynecol. Reprod. Biol. 85, 75-80 (1999).
26. Haile RW, Thomas DC, McGuire V et al. BRCA1 and BRCA2 mutation carriers, oral contraceptive use, and breast cancer before age 50. Cancer Epidemiol. Biomarkers Prev. 15, 1863-1870 (2006).
27. Marchbanks PA, McDonald JA, Wilson HG et al. Oral contraceptives and the risk of breast cancer. N. Engl J. Med. 346, 2025-2032 (2002).
28. Narod SA, Dube MP, Klijn J et al. Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J. Natl Cancer Inst. 94, 1773-1779 (2002).
29. CGHFBC. Familial breast cancer: Collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet 358, 1389-1399 (2001).
30. Brohet RM, Goldgar DE, Easton DF et al. Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: A report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group. J. Clin. Oncol. 25, 3831-3836 (2007).
31. Silvera SA, Miller AB, Rohan TE. Oral contraceptive use and risk of breast cancer among women with a family history of breast cancer: A prospective cohort study. Cancer Causes Control 16, 1059-1063 (2005).
32. Heimdal K, Skovlund E, Moller P. Oral contraceptives and risk of familial breast cancer. Cancer Detect. Prev. 26, 23-27 (2002).
33. Grabrick DM, Hartmann LC, Cerhan JR et al. Risk of breast cancer with oral contraceptive use in women with a family history of breast cancer. JAMA 284, 1791-1798 (2000).
34. Pasanisi P, Hedelin G, Berrino J et al. Oral contraceptive use and BRCA penetrance: A case-only study. Cancer Epidemiol. Biomarkers Prev. 18, 2107-2113 (2009).
35. Atchley DP, Albarracin CT, Lopez A et al. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J. Clin. Oncol. 26, 4282-4288 (2008).
36. Lee E, Ma H, McKean-Cowdin R et al. Effect of reproductive factors and oral contraceptives on breast cancer risk in BRCA1/2 mutation carriers and noncarriers: Results from a population-based study. Cancer Epidemiol. Biomarkers Prev. 17, 3170-3178 (2008).
37. Sade RB, Chetrit A, Figer A et al. Hormone replacement therapy is more prevalent among Jewish BRCA1/2 mutation carriers. Eur. J. Cancer 42, 650-655 (2006).
38. Milne RL, Knight JA, John EM et al. Oral contraceptive use and risk of early-onset breast cancer in carriers and noncarriers of BRCA1 and BRCA2 mutations. Cancer Epidemiol. Biomarkers Prev. 14, 350-356 (2005).
39. Ursin G, Henderson BE, Haile RW et al. Does oral contraceptive use increase the risk of breast cancer in women with BRCA1/BRCA2 mutations more than in other women? Cancer Res. 57, 3678-3681 (1997).
40. Iodice S, Barile M, Rotmensz N et al. Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: A meta-analysis. Eur. J. Cancer 46(12), 2275-2284 (2010). Meta-analysis presenting significant ovarian risk reduction (significant risk reduction: 0.50) in BRCA1/2 mutation carriers in relation to COC use and no evidence of increased breast cancer risk.
41. King MC, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302, 643-646 (2003).
42. Cibula D, Widschwendter M, Majek O, Dusek L. Tubal ligation and the risk of ovarian cancer: Review and meta-analysis. Hum. Reprod. Update 17(1), 55-67 (2010).
43. Evans DGR, Lalloo F, Ashcroft L et al. Uptake of risk-reducing surgery in unaffected women at high risk of breast and ovarian cancer is risk, age, and time dependent. Cancer Epidemiol. Biomarkers Prev. 18, 2318-2324 (2009).
44. Miller SM, Roussi P, Dally MB, Scarpato J. New strategies in ovarian cancer: Uptake and experience of women at high risk of ovarian cancer who are considering risk-reducing salpingo-oophorectomy. Clin. Cancer Res. 16, 5094-5106 (2010).